These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 7954524)

  • 41. In vitro effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine-activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer.
    Wang Z; Chen Y; Zheng R; Qin D; Chen X; Wang Y; Liu G
    Prostaglandins; 1997 Nov; 54(5):769-79. PubMed ID: 9491207
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565.
    Sodhi A; Basu S
    Nat Immun; 1992; 11(2):105-16. PubMed ID: 1498519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
    Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
    Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
    Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
    J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bryostatin-1 and IL-2 synergize to induce IFN-gamma expression in human peripheral blood T cells: implications for cancer immunotherapy.
    Curiel RE; Garcia CS; Farooq L; Aguero MF; Espinoza-Delgado I
    J Immunol; 2001 Nov; 167(9):4828-37. PubMed ID: 11673486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-1 and IL-4 as reciprocal regulators of IL-2 induced lymphocyte cytotoxicity.
    Ebina N; Gallardo D; Shau H; Golub SH
    Br J Cancer; 1990 Oct; 62(4):619-23. PubMed ID: 1699593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
    Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
    Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of human T lymphocytes by bryostatin.
    Hess AD; Silanskis MK; Esa AH; Pettit GR; May WS
    J Immunol; 1988 Nov; 141(10):3263-9. PubMed ID: 3263418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunological effects of flavone acetic acid.
    Triozzi PL; Rinehart JJ; Malspeis L; Young DC; Grever MR
    Cancer Res; 1990 Oct; 50(20):6483-5. PubMed ID: 2208107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of OK-432 on in vitro secondary responses of the non-adherent cells to IL-2 and OK-432 in cancer patients without tumor burden.
    Fujieda S; Saito H; Isobe Y; Nakagawara G; Nishi O; Nagahara K; Watanabe Y; Hoshino T
    Anticancer Res; 1993; 13(1):21-5. PubMed ID: 8476215
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction of NK and LAK activities in human lymphocyte culture by a cytosol fraction from leukemic myeloblasts and by monoclonal antibody CD 3.
    Soucek J; Chudomel V; Hrubá A; Lindnerová G
    Neoplasma; 1991; 38(1):33-41. PubMed ID: 2011208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-6 does not support interleukin-2 induced generation of human lymphokine-activated killer cells.
    Klingemann HG; Wong E
    Cancer Immunol Immunother; 1991; 33(6):395-7. PubMed ID: 1715237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human monocytes inhibit lymphokine-activated killer cell expansion in vitro.
    Triozzi PL; Aldrich WA; Rinehart JJ
    Mol Biother; 1991 Mar; 3(1):22-5. PubMed ID: 2069757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-induction of lymphokine synthesis by the antineoplastic bryostatins.
    Mohr H; Pettit GR; Plessing-Menze A
    Immunobiology; 1987 Nov; 175(5):420-30. PubMed ID: 3123367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells.
    Son YI; Dallal RM; Mailliard RB; Egawa S; Jonak ZL; Lotze MT
    Cancer Res; 2001 Feb; 61(3):884-8. PubMed ID: 11221875
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.
    Baxevanis CN; Voutsas IF; Soler MH; Gritzapis AD; Tsitsilonis OE; Stoeva S; Voelter W; Arsenis P; Papamichail M
    Immunopharmacol Immunotoxicol; 1998 Aug; 20(3):355-72. PubMed ID: 9736441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.